Vaxcyte Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.4%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$8.20next fiscal year
Monitoring Framework
Key Performance Indicators
VAX-31 OPUS-1 Phase 3 Pivotal Trial Enrollment Quarterly4KTarget: 4000 (Fully Enrolled)
VAX-31 OPUS-2 Phase 3 Trial Enrollment Quarterly1.3KTarget: 1300 (Fully Enrolled)
VAX-31 Infant Dose-Finding Study Enrollment Quarterly900.0Target: 900 (Fully Enrolled)
Watch Items
- VAX-31 OPUS-1 Phase 3 Pivotal Trial Topline DataTrigger: Topline safety, tolerability, and immunogenicity data releaseAction: Evaluate noninferiority compared to Prevnar 20 to support planned BLA submission.
- VAX-31 OPUS-2 and OPUS-3 Phase 3 Trial ResultsTrigger: Topline data release in first half of 2027Action: Assess concomitant administration with seasonal flu vaccine and performance in previously vaccinated adults.
- VAX-A1 Phase 1 Clinical Trial ProgressTrigger: Safety and tolerability updates in healthy adultsAction: Monitor clinical progression of the prophylactic Group A Strep vaccine candidate.
Research as of 28 Jul 2026